August Recognized in Chambers and Partners’ 2025 Guides for Excellence in Litigation and Crisis Communications

August is proud to have been recognized as a top advisor in Chambers and Partners’ 2025 guides for crisis and litigation communications support, advancing to Band 2 in the Crisis PR guide and maintaining our Band 2 ranking in the Litigation PR guide.

In addition to the firm’s rankings, Chief Executive Officer and Founding Partner Steven Goldberg and Partner Ellen Davis were honored individually as top-tier advisors. Steven advanced to a Band 2 advisor in this year’s litigation guide, and Ellen maintained her prior rankings in Bands 1 and 2 in the crisis and litigation guides, respectively.

Those interviewed by Chambers and Partners spoke to August’s specialized expertise and demonstrated results while navigating crisis and litigation matters on behalf of our clients:

  • “August is a go-to firm for us. We appreciate how nimble and efficient they are, even on the most complex matters.”

  • "August has a really strong, deep bench of experienced, smart people with significant ties to media. [The team] reacts quickly to inaccurate news reports and works its magic in resolving issues."

  • "August has outstanding expertise on legal matters coupled with media savvy."

As a young firm approaching our fourth anniversary, we are honored to have been recognized by Chambers and Partners for four consecutive years alongside the industry’s leading firms and practitioners. This achievement is a testament to our team’s dedication and excellence across industries and practice areas. We thank our clients and referral sources for their continued support and partnership.

August’s firm-wide and individual rankings can be viewed on the Chambers and Partners website:

Crisis PR & Communications

Litigation PR & Communications

Previous
Previous

From Division to Direction: Ethereum’s Leaders Rally Behind ETH’s Economic Story

Next
Next

“Stomp[ing] Loudly and Wield[ing] a Wet Noodle”: Analyzing the Rollout of President Trump’s Plan to Lower Pharmaceutical Drug Prices